193 related articles for article (PubMed ID: 29386360)
1. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
Ravà M; D'Andrea A; Nicoli P; Gritti I; Donati G; Doni M; Giorgio M; Olivero D; Amati B
Sci Transl Med; 2018 Jan; 10(426):. PubMed ID: 29386360
[TBL] [Abstract][Full Text] [Related]
2. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
3. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
5. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
[TBL] [Abstract][Full Text] [Related]
6. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
9. Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.
Donati G; Ravà M; Filipuzzi M; Nicoli P; Cassina L; Verrecchia A; Doni M; Rodighiero S; Parodi F; Boletta A; Vellano CP; Marszalek JR; Draetta GF; Amati B
Mol Oncol; 2022 Mar; 16(5):1132-1152. PubMed ID: 34632715
[TBL] [Abstract][Full Text] [Related]
10. MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.
Bisso A; Sabò A; Amati B
Immunol Rev; 2019 Mar; 288(1):178-197. PubMed ID: 30874346
[TBL] [Abstract][Full Text] [Related]
11. Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Pan G; Zhong M; Yao J; Tan J; Zheng H; Jiang Y; Tang Y; Zhou H; Qin D; Yu X; Liu L; Li Z; Lin Z; Jiang Y; Xu B; Zha J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5513-5529. PubMed ID: 36471019
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
14. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
15. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
[TBL] [Abstract][Full Text] [Related]
16. CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With
Yuan D; Li G; Yu L; Jiang Y; Shi Y; Chen Q; Ma X; Pham LV; Young KH; Deng M; Fang Z; Xu B
Front Oncol; 2021; 11():618908. PubMed ID: 33777762
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
[TBL] [Abstract][Full Text] [Related]
18. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
19. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
20. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
